Yuhan Joins Immuno-Oncology Wave Via Sorrento JV
This article was originally published in PharmAsia News
One of South Korea's leading pharma firms, Yuhan, is joining the global immuno-oncology wave by setting up a majority-owned joint venture with US-based Sorrento Therapeutics. The JV, Yuhan’s first in R&D, is set to develop and commercialize three of Sorrento's immune checkpoint antibodies.
You may also be interested in...
Yuhan and Luoxin's licensing agreement for a third generation EGFR inhibitor, the second such deal between South Korea and China, suggests robust demand for novel drugs for non-small cell lung cancer in Asia.
South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.
Although the pandemic could slightly delay CrystalGenomics’ business and R&D plans, the South Korean biotech is still hopeful this year will bring long-awaited progress for anticancer candidate ivaltinostat as well as discovery of its potential as a treatment for the new coronavirus.